Woojeong Bio and Hallym University Dongtan Sacred Heart Hospital Sign Agreement to Activate 'New Drug Cluster'

Director Seongho Lee (left) of Hallym University Dongtan Sacred Heart Hospital and Byeongnyeon Cheon, CEO of Woojeong Bio, are signing a business agreement and taking a commemorative photo.

[Asia Economy Reporter Lee Gwan-joo] Woojung Bio announced on the 2nd that it has signed a business agreement with Hallym University Dongtan Sacred Heart Hospital for joint research and the establishment and activation of a new drug cluster.

Through this agreement, both parties agreed to work together to early discover promising research and commercializable ideas, establish various open innovation support systems, promote joint research and development, exchange human resources, and provide networking opportunities such as curriculum, joint workshops, and technical consulting.

Lee Seong-ho, the hospital director, said, “We expect synergy between the hospital’s research and development capabilities and Woojung Bio’s outstanding new drug development infrastructure,” adding, “We will spare no support to activate projects in various fields through this agreement.”

Cheon Byeong-nyeon, CEO of Woojung Bio, stated, “Through the agreement with the hospital that plays a key role in the clinical sector, new drug development companies preparing for clinical entry will be able to receive a higher level of research infrastructure and clinical solutions,” and added, “In the future, we will jointly conduct national research projects with the hospital to further develop the hardware and software capabilities of the Woojung Bio new drug cluster.”

This content was produced with the assistance of AI translation services.